Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07452874Recruiting
Occupational therapy for Syrian refugees to boost social life
This study tests whether community-based occupational therapy can help Syrian refugees improve their social participation and daily activities. It may be a good fit if you are a Syrian refugee who speaks Turkish and can attend sessions regularly.
IstanbulAges 18–65 - NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
Rochester, MinnesotaAges 18–60 - NCT06487559RecruitingPhase 1
Studying livmoniplimab plus budigalimab for advanced liver cancer
This study tests a combination of two investigational drugs given through a vein to see how they work in Chinese adults with advanced liver cancer that has already been treated with one immunotherapy. The goal is to find out if this new two-drug combination is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06488313RecruitingPhase 2
Study of ARCT-810 for people with OTC deficiency
This trial tests an experimental medicine called ARCT-810 for people with Ornithine Transcarbamylase (OTC) deficiency, a condition that affects the liver's ability to remove ammonia from the body. The study aims to see if ARCT-810 can help lower ammonia levels safely.
Chevy Chase, MarylandAges 12 years+ - NCT06507748Recruiting
Measuring pain with a finger device in NF1
This study tests a new way to measure pain and other sensations in people with NF1 using a device that clips onto a finger or toe. The device looks at how your pupil reacts to mild pulses, which may help doctors better understand your pain.
Washington D.C., District of ColumbiaAges 1–120 - NCT06514001RecruitingPhase 2
Testing a new drug for Alzheimer's disease with eye scans
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
Phoenix, ArizonaAges 18 years+ - NCT06517628Recruiting
Heart health in pregnancy: a study for moms and babies
This study follows pregnant women with heart conditions to understand how pregnancy affects their heart health and their baby's health. You may join if you have one or more heart conditions, such as a heart defect, a heart infection, an irregular heartbeat, or a blood vessel problem.
Kansas City, MissouriAges 18 years+ - NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06522737RecruitingPhase 3
Duvelisib vs chemotherapy for relapsed T-cell lymphoma
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
GhentAges 18 years+ - NCT06524622Recruiting
Ultrasound and pressure test for sepsis in the ICU
This study tests whether a special ultrasound exam (VExUS) combined with a standard pressure measurement (CVP) can better predict outcomes for people with sepsis in the ICU. The goal is to see if these tools help doctors make better treatment decisions.
Yibin, SichuanAges 18–100 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT06526364Recruiting
Multiple sclerosis study with smartphone app tracking
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
BaselAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06533137Recruiting
How your mind can influence the placebo effect
This trial studies how your awareness and personal beliefs affect the placebo effect—a real improvement in symptoms from a treatment that has no active medicine. Researchers are looking at healthy people to understand how the mind and body interact, which could help improve future treatments.
MilanAges 18 years+ - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+ - NCT06537596RecruitingPhase 1
Testing a new imaging agent for soft tissue sarcoma
This trial tests a special imaging agent (89Zr-olaratumab) that may help doctors see soft tissue sarcoma tumors more clearly. It could help determine if a targeted therapy could work for you.
Melbourne, VictoriaAges 18 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06546449RecruitingPhase 1
Testing LH-001 Safety in Healthy Adults
This study tests a new medicine called LH-001 in healthy volunteers to see if it is safe. You will receive either the medicine or a placebo (a dummy pill) and stay overnight for monitoring.
Columbus, OhioAges 18–60 - NCT06547775RecruitingPhase 1
Study of KN069 for people with obesity or overweight
This trial tests a new drug called KN069 to see if it can help people who are overweight or have obesity. It may offer a new treatment option for weight management.
Changsha, HunanAges 18–55 - NCT06548542RecruitingPhase 2
Targeted therapy study for moderate to severe Crohn's disease
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06549309RecruitingPhase 1
Early safety study of JMKX003801 in healthy adults
This early-stage study tests whether a new oral drug (JMKX003801) is safe in healthy volunteers. It helps find the right dose and checks for side effects.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06555419RecruitingPhase 1
How Nusinersen works with ThecaFlex DRx system
This study looks at how a medicine called Nusinersen (Spinraza) works in the body when given through a new device called ThecaFlex DRx. It is for people with spinal muscular atrophy who are already on a steady dose of Nusinersen and are part of the main PIERRE study.
Orange, CaliforniaAges 3 years+ - NCT06559306RecruitingPhase 3
Seltorexant for depression with insomnia symptoms
This trial tests if adding seltorexant to your current antidepressant can improve depression and sleep problems. It is for people with major depressive disorder who still have symptoms, especially insomnia, despite trying at least one antidepressant.
Birmingham, AlabamaAges 18–74
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.